arsenic has been researched along with Ataxia Telangiectasia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| He, Q; Ke, Z; Liang, C; Lin, R; Liu, H; Meng, J; Miao, Z; Wang, H; Wen, L; Zha, Z; Zhang, L; Zhang, M | 1 |
| Gupta, S; Maslov, AY; Sharma, Y; Tchaikovskaya, T; Thirunavukkarasu, C | 1 |
| Menéndez, D; Mora, G; Ostrosky-Wegman, P; Salazar, AM | 1 |
3 other study(ies) available for arsenic and Ataxia Telangiectasia
| Article | Year |
|---|---|
PSMA-targeted arsenic nanosheets: a platform for prostate cancer therapy via ferroptosis and ATM deficiency-triggered chemosensitization.
Topics: Arsenic; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Ferroptosis; Glutathione; Humans; Male; Prostatic Neoplasms | 2021 |
Transcriptional profiling reveals ataxia telangiectasia mutated pathways regulate joint copper and arsenic toxicity for hepatic metalloplasia and anti-cancer therapies.
Topics: Arsenic; Ataxia Telangiectasia; Copper; Humans; Liver; RNA, Messenger | 2022 |
ATM status confers sensitivity to arsenic cytotoxic effects.
Topics: Arsenic; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Carcinogens; Cell Cycle Proteins; Cell Line, Transformed; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA-Binding Proteins; Humans; Lymphocyte Activation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2001 |